Search details
1.
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Oncologist
; 26(7): e1104-e1109, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33742489
2.
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.
Invest New Drugs
; 37(1): 147-158, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30056611
3.
Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
Invest New Drugs
; 37(2): 315-322, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30191522
4.
One Step at a Time - Clinical Evidence That KRAS Is Indeed Druggable.
N Engl J Med
; 383(13): 1277-1278, 2020 09 24.
Article
in English
| MEDLINE | ID: mdl-32955175
5.
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.
Invest New Drugs
; 36(1): 36-44, 2018 02.
Article
in English
| MEDLINE | ID: mdl-28417284
6.
Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
Invest New Drugs
; 36(6): 1158, 2018 12.
Article
in English
| MEDLINE | ID: mdl-30334109
7.
Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.
Future Oncol
; 14(7): 589-602, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-29214842
8.
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Lancet Oncol
; 18(6): 743-754, 2017 06.
Article
in English
| MEDLINE | ID: mdl-28526538
9.
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Invest New Drugs
; 35(5): 576-588, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28424891
10.
Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
Invest New Drugs
; 35(4): 442-450, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28161886
11.
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
BMC Cancer
; 17(1): 173, 2017 03 06.
Article
in English
| MEDLINE | ID: mdl-28264648
12.
SARS-CoV-2 vaccination and phase 1 cancer clinical trials.
Lancet Oncol
; 22(3): 298-301, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33571468
13.
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res
; 18(1): 34, 2016 Mar 15.
Article
in English
| MEDLINE | ID: mdl-26979312
14.
Preclinical and first-in-human phase I studies of KW-2450, an oral tyrosine kinase inhibitor with insulin-like growth factor receptor-1/insulin receptor selectivity.
Cancer Sci
; 107(4): 499-506, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26850678
15.
A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.
Br J Cancer
; 114(8): 889-96, 2016 Apr 12.
Article
in English
| MEDLINE | ID: mdl-27002938
16.
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.
Invest New Drugs
; 34(1): 84-95, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26620496
17.
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 33(2): 349-56, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25476894
18.
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
Invest New Drugs
; 33(2): 440-9, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25684345
19.
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
Anticancer Drugs
; 26(7): 785-92, 2015 Aug.
Article
in English
| MEDLINE | ID: mdl-26020806
20.
A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.
Future Oncol
; 11(10): 1479-91, 2015.
Article
in English
| MEDLINE | ID: mdl-25963426